cyclotherapeutics.com - CYTH Profit before deduction of interest, taxes, depreciation and amortization
Cyclo Therapeutics focuses on the therapy of rare genetic pathologies, leveraging support from the Rafael fund and FDA status. The company is currently finalizing trials of Trappsol Cyclo to combat Niemann-Pick disease. The EBITDA growth trajectory helps assess financial stability, where the mark reflects the latest data. Drug development has been accelerated through robotics and digital process modeling.
Summary analytical data breakdowns for Cyclo Therapeutics, Inc. (CYTH)
- stock value and consensus price forecast:
- issuer market value details:
- book capitalization indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Cyclo Therapeutics|CYTH - Long-Term Debt to Equity|Current Liabilities to Equity Cyclo Therapeutics Inc.|CYTH - Company Aggregate Debts|Debt to Net Assets Ratio Cyclo Therapeutics|CYTH - Company Long-Term Debts|Company Short-Term Debts Cyclo Therapeutics|Intermediate Coverage Ratio cyclotherapeutics.com
- earnings and market multiples details:
CYTH - Company Net Income|Future Profit Cyclo Therapeutics|CYTH - P/E Multiple|Forward P/E Multiple cyclotherapeutics.com|CYTH - PEG Multiple|Enterprise Value to EBITDA Ratio Cyclo Therapeutics|CYTH - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Cyclo Therapeutics|CYTH - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months cyclotherapeutics.com|CYTH - Earnings per share growth in current year|Net earnings per share growth forecast for next year Cyclo Therapeutics
Summary company analytics:Cyclo Therapeutics, Inc
To isolate fundamental stability from market noise, it is essential to evaluate cash flow from operating activities, excluding the impact of borrowing costs and depreciation. This operating financial result demonstrates the business's actual ability to generate cash, which is critical for Cyclo Therapeutics (CYTH) during a period of maximum resource concentration on completing the phase 3 clinical trials of the drug.
Who Cyclo Therapeutics competes with
Operating income before deduction of amortization Vertex Corp (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BioMarin Pharmaceutical Inc. (BMRN)|BBIO (BridgeBio Pharma Inc) - Operating profit EBITDA|Operating profit before amortization BGM (BGM Group Corp)|Operating profit before deduction of amortization COGT (Cogent Biosciences)|XERS (xerispharma.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Keros Therapeutics, Inc. KROS|ARCT (Arcturus Therapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Eton Pharma - Operating profit EBITDA|Income before deduction of interest, taxes and amortization KMDA (Kamada Pharma)|FULC: Operating profit EBITDA|Abeona Therapeutics Inc. (ABEO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Mereo BioPharma Group|PLX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pliant Therapeutics (PLRX)|Operating profit before deduction of amortization appliedtherapeutics.com APLT|Operating profit EBITDA RNTX (Rein Therapeutics Inc)|Operating profit EBITDA Gelteq Ltd GELS|Aytu Therapeutics - Operating profit EBITDA|Chemomab Therapeutics (CMMB) - Operating profit before deduction of amortization|SRXH (srxhealth.com) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Polyrizon (PLRZ)|AEZS (Aeterna Zentaris Inc) - Operating profit EBITDA|Operating profit before deduction of amortization Inozyme (INZY)|Profit before payment of interest, taxes and amortization Reneo Pharmaceuticals, Inc. (RPHM)|Profit before payment of interest, taxes and amortization CSCI (COSCIENS Biopharma Inc)
